Insulet (Nasdaq:PODD) shares got a boost today on fourth-quarter results that came in ahead of the consensus forecast.
Shares of PODD ticked up more than 8% to $266.10 apiece in morning trading today.
The Acton, Massachusetts–based automated insulin delivery technology developer reported profits of $101.6 million. That equals $1.44 per share on sales of $783.8 million for the three months ended Dec. 31, 2025.
Insulet recorded a 0.9% bottom-line gain on a sales increase of 31.2%.
Adjusted to exclude one-time items, earnings per share came in at $1.55. That landed 9¢ ahead of expectations on Wall Street. Sales topped the forecast, too, as experts projected $768.7 million in revenue.
In the quarter, total Omnipod revenue reached $2.7 billion, marking a rise of 31.6%. The company also said it ranked first in new customer starts in both the U.S. and Europe in 2025, achieving record new customer starts in Q4 and for the full year. Insulet also said it received approval from its board for a $350 million increase in its share repurchase authorization. It expects to allocate approximately $300 million toward repurchases in the first quarter of 2026 using existing cash.
Read more about Insulet, its technology, and the rest of the diabetes tech industry in our free Diabetes Technology Special Report.
President and CEO Ashley McEvoy outlined some of the future plans for Omnipod in an interview with Drug Delivery Business News last fall, while she and other Insulet leaders expanded on those plans during the company’s November Investor Day event. Those plans include next-generation platforms and algorithms, among other advancements.
Insulet did not provide specific figures on its 2026 guidance but anticipates sales growth between 20% and 22% and adjusted EPS growth greater than 25% year-over-year.
“We ended the year with another excellent quarter, demonstrating the power of our business model, the strength of our technology, and the disciplined execution of our team,” McEvoy said. “Our performance shows that Insulet continues to lead with innovation, scale, and customer trust — and that our competitive position has never been stronger. As we move into 2026, we are confident in our ability to grow the global AID market, expand adoption across type 1 and type 2 diabetes, and deliver on the strategic and financial commitments we have laid out. Insulet has the talent, the technology, and the momentum to lead this category for the long term.”
(McEvoy will be a keynote speaker at DeviceTalks Boston May 27-28. Learn more and register here.)
Insulet leadership expands on next-gen tech
McEvoy and Insulet leadership first outlined plans for Omnipod 6, the next-generation pump system, at that November investor day.
Omnipod 6 represents the next-generation hybrid closed-loop automated insulin delivery (AID) option for both type 1 and type 2 diabetes. It features an improved, adaptive algorithm that makes the pod even easier to use, McEvoy said in November.
On the company’s fourth-quarter earnings call, McEvoy continued to expand on what to expect from the technology. The company plans to share pivotal data for the system at the American Diabetes Association’s Scientific Sessions in June.
“This system is designed to address the critical needs of users by meaningfully reducing day to day burden and increasing flexibility for improved connectivity, expanded flexibility in on-body placement, real-time software updates and more personalized automation,” McEvoy said. “Importantly, we are designing a single, updatable Pod platform that will be compatible across all CGM systems. These capabilities not only improve outcomes and the wear experience, but also accelerate our innovation cycle as we prepare for launch in 2027.”
The next step in Insulet’s innovation roadmap comes in 2028, with the planned launch of a new, fully closed-loop system. This system’s algorithm adjusts intelligently in real-time with no need for meal announcements, carb counting or manual input. McEvoy and COO Eric Benjamin say such a system would make automated insulin delivery accessible to “virtually everyone.”
“We believe that we are in a class by ourselves in how we’re going to define what fully closed-loop really means,” Benjamin said.
Other advances to look forward to
Insulet also plans to deliver “highly requested” enhancements to reinforce its leadership in 2026. That includes algorithm updates that enable new targets for tighter glycemic control, increased time in automated mode and improved responsiveness.
The company also plans to expand its CGM integrations to include the Abbott FreeStyle Libre 3 Plus, having already made Omnipod 5 available with the Dexcom G7 15 Day, the latest offering from Dexcom. McEvoy said this would make Omnipod 5 compatible with every major sensor.
Insulet also plans to make Omnipod Discover available globally. Discover is a proprietary and retrospective data analytics and reporting platform that was designed for Omnipod 5 users, their caregivers and healthcare providers. It streamlines the analysis of glucose and insulin delivery data to deliver meaningful insights.
The company also plans to target the type 2 bolus market, then target type 2 basal over time. It recently completed enrollment for EVOLUTION-2, a safety and feasibility study. It also fully enrolled STRIVE, the pivotal study for its next-generation algorithm.
“Collectively, these enhancements reduce day-to-day effort with fewer device interactions, broader CGM choice and more actionable insights that help patients and clinicians with confidence,” McEvoy said.
The analysts’ take
BTIG analysts Marie Thibault, Sam Eiber and Alexandra Pang maintained a “Buy” rating for Insulet. They highlighted the “sweet spot” in which Insulet currently resides with its record new starts, market potential and ability to increase presentation.
They noted Insulet management’s emphasis on the under-penetrated automated insulin delivery, especially in type 2 diabetes and outside the U.S.
Insulet remains confident in future penetration with high-volume prescribers, investment in direct-to-consumer (DTC) campaigns, optimized costs and focused messaging.
“For us, Q4 showed momentum in patient starts and durable sales growth that will be supported by pipeline efforts. We reiterate our Buy rating,” the analysts wrote.
